XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Equity | 12 Months Ended
--- | ---
Dec. 31, 2017
Equity [Abstract] |
Equity | NOTE 16 – EQUITY Authorized Capital As of December 31, 2017, the Company was authorized to issue 100,000,000 shares of no par value common stock. The holders of the Company’s common stock are entitled to one vote per share. Common Stock Issuances On July 21, 2017, the Company issued 6,696 shares of common stock of the company to an investor at a purchase price of $7.47 per share providing $50,000 of proceeds to the Company. On August 25, 2017, the Company issued an aggregate of 42,856 shares of common stock of the company to investors at a purchase price of $7.47 per share providing $320,000 of proceeds to the Company. On September 1, 2017, the Company issued 6,698 shares of common stock of the company to an investor at a purchase price of $7.47 per share providing $50,000 of proceeds to the Company. During the year ended December 31, 2017, the Company issued 1,314,753 shares of its common stock upon conversion of various ARH Notes in the aggregate principal amount of $5,361,177 (See Note 10 – Convertible Notes Payable to Former Parent). Stock Option and Stock Issuance Plan The Company’s board of directors and shareholders adopted and approved on July 27, 2017 and September 21, 2017, respectively, the Stock Option and Stock Issuance Plan (“2017 Plan”), effective September 21, 2017, under which stock options and restricted stock may be granted to officers, directors, employees and consultants. Under the 2017 Plan, the company reserved 1,071,428 shares of common stock, no par value per share, for issuance. As of the date of the issuance of these consolidated financial statements 1,039,292 shares of common stock were outstanding under the 2017 Plan. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Options Granted On July 27, 2017, the Company issued stand-alone non-qualified stock options, not pursuant to a plan, to purchase an aggregate of 33,750 shares of the Company’s common stock to its franchisees. The options are fully vested on the date of issuance and have an exercise price of $9.33 per share. The options expire three years from the date of issuance. The options have a grant date value of $47,583. The Company has estimated the fair value of the options granted using the Black-Scholes model using the following assumptions: expected volatility of 37%, risk-free rate of 1.52%, expected term of 3 years, expected dividends of 0%, and stock price of $7.47. Restricted Common Stock Issuances In May 2017, Muscle Maker granted 119,709 shares of its restricted common stock to its employees and consultants, with an aggregate grant date value of $1,117,403 or $9.33 per share. The restricted common stock awards granted to the employees will vest in five equal installments with the first installment vesting on the date of grant and the remaining installments vesting on the first day of each of the next four calendar years thereafter. In the event of resignation or termination for any reason of an employee or consultant that received such shares, any remaining non-vested shares will be forfeited. These awards were granted under the 2017 Plan. Effective July 20, 2017, the Company entered into a Master Services Agreement (the “MSA”), with a consultant for marketing services to the Company in connection with the Regulation A + offering. Pursuant to the terms of the MSA, the Company issued 52,307 shares of fully vested restricted common stock at a value of $3.25 per share with an aggregate value of $170,000, as well as a cash fee of $145,000. On September 21, 2017, the Company granted an aggregate amount of 32,136 shares of its restricted common stock at a price of $9.33 per share to its directors. The restricted common stock awards granted to the directors are subject to graded vesting in the following installments: (i) 66.67% as of the date of grant and (ii) four installments of 8.333% vesting on the first day of each of the next four calendar months. At December 31, 2017, the unamortized value of the restricted common stock was $662,940. The unamortized amount will be expensed over a weighted average period of 3.01 years. A summary of the activity related to the restricted common stock for the year ended December 31, 2017 is presented below:
|  |  |  |  | Weighted |
|  |  |  |  | Average Grant |
|  | Total |  |  | Date Fair Value |
Outstanding at January 1, 2017 |  |  | - |  |  | $ | - |
Granted |  |  | 204,152 |  |  |  | 7.78 |
Forfeited |  |  | (1,285 | ) |  |  | 9.33 |
Vested |  |  | (105,690 | ) |  |  | 6.32 |
Outstanding at December 31, 2017 |  |  | 97,177 |  |  | $ | 6.82 |
Stock-Based Compensation Expense Stock-based compensation related to restricted stock issued to employees, directors and consultants amounted to $912,485 and $3,684 for the years ended December 31, 2017 and 2016, respectively, of which $729,073 and $3,684, respectively, was recorded in general and administrative expenses, $13,748 and $0, respectively, was recorded in labor expense with restaurant operating expenses and $170,000 and $0, respectively, was recorded in consulting expenses. Stock-based compensation related to options issued to franchisees amounted to $47,583 year ended December 31, 2017 of which was offset against franchisee royalties and fees in the statement of operations. Warrants On April 21, 2016, the Company granted a three-year warrant for the purchase of 5,356 shares of the Company’s common stock at an exercise price of $9.33 per share to a franchisee and developer of the Company in exchange for services. The warrant had a grant date value of $3,684. On July 25, 2017, a warrant was exercised for the 5,356 shares of common stock of the Company at an exercise price of $9.33 per share for gross proceeds of $50,000. A summary of warrants activity during the years ended December 31, 2017 and 2016 is presented below (See Note 10 —Convertible Notes Payable to Former Parent and Note 11 —Other Notes Payable for warrants issued during the year ended December 31, 2017):
|  |  |  |  |  |  |  | Weighted |
|  |  |  |  | Weighted |  |  | Average |
|  |  |  |  | Average |  |  | Remaining |
|  | Number of |  |  | Exercise |  |  | Life |
|  | Warrants |  |  | Price |  |  | In Years |
Outstanding, December 31, 2015 |  |  | - |  |  | $ | - |  |  |  | - |
Issued |  |  | 318,116 |  |  |  | 8.84 |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |
Outstanding, December 31, 2016 |  |  | 318,116 |  |  | $ | 8.84 |  |  |  | 2.2 |
Issued |  |  | 208,285 |  |  |  | 9.33 |  |  |  |  |
Exercised |  |  | (5,356 | ) |  |  | 9.33 |  |  |  |  |
Outstanding, December 31, 2017 |  |  | 521,045 |  |  |  | 9.03 |  |  |  | 1.9 |
Exercisable, December 31, 2017 |  |  | 521,045 |  |  | $ | 9.03 |  |  |  | 1.9 |
The grant date fair value of warrants granted during the years ended December 31, 2017 and 2016 was determined on the date of issuance using the Black-Scholes option pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical volatility of comparable companies over the most recent period equal to the expected term and evaluates the extent to which available information indicates that future volatility may differ from historical volatility. The expected dividend rate is zero as the Company does not expect to pay or declare any cash dividends on common stock. The risk-free rates for the expected terms of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected term of its stock option awards issued using the simplified method. In applying the Black-Scholes option pricing model, the Company used the following assumptions:
|  | For the Years Ended |
|  | December 31, |
|  | 2017 |  |  | 2016 |
Risk free interest rate |  |  | 1.07% - 1.59 | % |  |  | 1.61 | %
Expected term (years) |  |  | 3.00 |  |  |  | 3.00 |
Expected volatility |  |  | 43.50 | % |  |  | 40.00 | %
Expected dividends |  |  | 0.00 | % |  |  | 0.00 | %

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration